Table 1 Baseline SjS-related features and risk of development of solid and hematological cancer
From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome
Baseline features | Values at diagnosis (n = 1300) | Solid cancer (n = 70) | Hematological cancer (n = 61) |
|---|---|---|---|
Age at diagnosis | 54.8 ± 15.4 | † | † |
Gender (male) | 99 (7.6) | † | † |
Ethnicity (white) | 1246 (95.8) | 0.41 [0.10–1.71] | 0.99 [0.14–7.29] |
Dry mouth | 1299 (99.9) | – | – |
Dry eye | 1234 (94.9) | 0.48 [0.19–1.20] | 1.37 [0.33–5.63] |
Altered ocular tests | 1013/1156 (87.6) | 1.29 [0.47–3.58] | 5.38 [0.74–39.03] |
Altered parotid scintigraphy | 835/992 (84.2) | 0.87 [0.41–1.86] | 1.34 [0.53–3.41] |
Positive salivary gland biopsy | 497/629 (79) | 0.92 [0.35–2.44] | 1.01 [0.42–2.45] |
Anemia (Hb < 110 g/L) | 216/1297 (16.7) | 1.05 [0.59–1.86] | 2.07 [1.20–3.58] ‡ |
Leukopenia (<4000/mm3) | 227/1297 (17.5) | 1.49 [0.87–2.55] | 0.96 [0.50–1.86] |
Thrombocytopenia (<150,000/mm3) | 87/1297 (6.7) | 1.18 [0.54–2.57] | 1.17 [0.50–2.72] |
Neutropenia (<1500/mm3) | 137/1296 (10.6) | 1.41 [0.74–2.71] | 1.66 [0.83–3.32] |
Lymphopenia (<1000/mm3) | 141/1295 (10.9) | 1.80 [0.96–3.35] | 1.43 [0.71–2.86] |
Antinuclear antibodies+ | 1124/1295 (86.8) | 0.95 [0.49–1.85] | 1.05 [0.50–2.21] |
Rheumatoid factor+ | 583/1245 (46.8) | 1.13 [0.71–1.82] | 1.08 [0.65–1.80] |
Anti-Ro/SS-A+ | 981/1294 (75.8) | 1.43 [0.81–2.53] | 1.28 [0.70–2.36] |
Anti-La/SS-B+ | 626/1289 (48.6) | 0.99 [0.62–1.60] | 1.17 [0.69–1.97] |
Monoclonal gammopathy | 114/1018 (11.2) | 1.94 [0.99–3.80] | 2.13 [1.08–4.19] |
Cryoglobulins+ | 70/929 (7.5) | 0.70 [0.25–1.94] | 4.37 [2.32–8.22] ‡ |
Low C3 levels (<0.82 g/L) | 144/1233 (11.7) | 0.59 [0.21–1.62] | 2.07 [1.06–4.03] |
Low C4 levels (<0.11 g/L) | 163/1218 (13.4) | 1.07 [0.51–2.24] | 2.23 [1.17–4.26] |